A combination of l-arabinose and chromium lowers circulating glucose and insulin levels after an acute oral sucrose challenge
1 Integrative Health Technologies, Inc. San Antonio, TX 78209, USA
2 Business and Healthcare Consultants, San Antonio, TX, 78209, USA
3 Michigan State University College of Human Medicine, East Lansing, MI, 48824-136, USA
4 Georgetown University Medical Center, Departments of Biochemistry, Medicine and Pathology, Washington, DC, 20057, USA
Nutrition Journal 2011, 10:42 doi:10.1186/1475-2891-10-42Published: 6 May 2011
A growing body of research suggests that elevated circulating levels of glucose and insulin accelerate risk factors for a wide range of disorders. Low-risk interventions that could suppress glucose without raising insulin levels could offer significant long-term health benefits.
To address this issue, we conducted two sequential studies, the first with two phases. In the first phase of Study 1, baseline fasting blood glucose was measured in 20 subjects who consumed 70 grams of sucrose in water and subsequently completed capillary glucose measurements at 30, 45, 60 and 90 minutes (Control). On day-2 the same procedure was followed, but with subjects simultaneously consuming a novel formula containing l-arabinose and a trivalent patented food source of chromium (LA-Cr) (Treatment). The presence or absence of the LA-Cr was blinded to the subjects and testing technician. Comparisons of changes from baseline were made between Control and Treatment periods. In the second phase of Study 1, 10 subjects selected from the original 20 competed baseline measures of body composition (DXA), a 43-blood chemistry panel and a Quality of Life Inventory. These subjects subsequently took LA-Cr daily for 4 weeks completing daily tracking forms and repeating the baseline capillary tests at the end of each of the four weeks. In Study 2, the same procedures used in the first phase were repeated for 50 subjects, but with added circulating insulin measurements at 30 and 60 minutes from baseline.
In both studies, as compared to Control, the Treatment group had significantly lower glucose responses for all four testing times (AUC = P < 0.0001). Additionally, the Treatment was significantly more effective in lowering circulating insulin after 60 minutes from baseline (AUC = P = < 0.01). No adverse effects were found after acute sucrose challenge or in those who consumed LA-Cr daily for four weeks.
As compared to a placebo control, consumption of a LA-Cr formula after a 70-gram sucrose challenge was effective in safely lowering both circulating glucose and insulin levels.
Clinical Trials.gov, NCT0110743